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Background. In stress echocardiography, contrast agents are used selectively to improve endocardial border deﬁnition. Early
identiﬁcationofcandidatesmayfacilitateuseoftheseagentsinsmallandmediumvolumelaboratorieswhereresourcesarelimited.
Methods. We studied 15232 patients who underwent stress echocardiography. Contrast agent was used if 2 or more ventricular
segmentswerenotadequatelyvisualizedwithoutcontrast.Logisticregressionmodelswereusedtoevaluatetheassociationbetween
individual characteristics and contrast use. An 11-point score was derived from the signiﬁcant characteristics. Results. Variables
associated with microbubble use were age, sex, smoking, presence of multiple risk factors, bodymass index (BMI), referral for
dobutamine stress echocardiography, history of coronary artery disease, and abnormal baseline electrocardiogram. All variables
except BMI were given a score of 1 if present and 0 if absent; BMI was given a score of 0 to 4 according to its value. An increased
score was directly proportional to increased likelihood of contrast use. The score cutoﬀ value to optimize sensitivity and speciﬁcity
was 5. Conclusions. A pretest score can be computed from information available before imaging. It may facilitate contrast agent use
through early identiﬁcation of patients who are likely to beneﬁt from improved endocardial border deﬁnition.
Copyright © 2009 Mathieu Bernier et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Obtaining a satisfactory image in patients with certain
characteristics, including obesity, chest wall deformities, and
severe obstructive pulmonary disease, continues to be a
challenge in diagnostic echocardiography. In these patients,
stress echocardiography presents an even greater challenge
because deﬁnition of the endocardial border is often worse
during or immediately after the applied stress [1]. This
reduced endocardial border deﬁnition is partly due to
increased chest wall motion related to tachypnea and heart
movement due to tachycardia. With fundamental imaging,
as many as 30% of studies show inadequate endocardial
deﬁnition [2] and may be nondiagnostic.
Numerous transpulmonary microbubble contrast agents
have been shown to have an incremental beneﬁt over
harmonic imaging for detection of endocardial border in
selected patients and have now been approved by the US
Food and Drug Administration for left ventricular opaciﬁ-
cation [1, 3]. Use of microbubble contrast agents in stress
echocardiography improves endocardial border deﬁnition
and accuracy to a degree in which a technically “inadequate”
study with incomplete endocardial visualization can be
rendered interpretable and have sensitivity and speciﬁcity
comparable to an “adequate” study [4]. Figure 1 shows an
example of inadequate endocardial border deﬁnition with
harmonic imaging improved with microbubble contrast
agent use.
Candidatesforuseofmicrobubblecontrastagentsduring
stress echocardiography are usually identiﬁed on the basis of
suboptimal or inadequate resting images. Performance of a
contrast echocardiographic study requires that (1) approval
for contrast use is obtained from a physician, (2) intravenous
access is achieved, and (3) the presence of appropriately2 Cardiology Research and Practice
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Figure 1: (a) Apical 4-chamber view (left ventricle on right, end-diastole) with harmonic imaging. (b) Same view with enhancement due to
intravenous microbubble contrast agent. Image shows marked improvement of endocardial border deﬁnition, especially at apex and in mid
segment of anterolateral wall.
qualiﬁed personnel are available. This sequence of events
may increase procedure time, decrease laboratory through-
put, and reduce patient satisfaction. Thus, some centers
have adopted strategies to decrease the time required to
initiate a contrast study. An example of such a strategy
is the development of a standing order that allows a
qualiﬁed nurse or sonographer to proceed directly with
the preparation and administration of microbubble contrast
agents for left ventricular opaciﬁcation [5, 6]. However, such
a strategy relies on the initial acquisition of resting images
and consumes time, termed struggle time, before a decision
is made to proceed [7]. The use of intravenous microbubble
contrastagentshaspreviouslybeenshowntobeaccurateand
cost-eﬀective [4, 8]. We sought to test predictors of contrast
agent use and to develop a simple score that integrates those
predictors. We required that the score was easily calculated at
patient presentation and was readily computable before any
image acquisition.
2. Methods
2.1. Population. We identiﬁed 16052 consecutive patients
who had a clinically indicated stress echocardiogram at our
laboratory between November 2003 and November 2005.
Information on the use of microbubble contrast agents was
available in 15253 patients (95%); the data from these
patients were included in the analysis. From November 2003
to July 2004, the decision to use a microbubble contrast
agent was made on an individual, case-by-case basis whereby
the physician reviewed resting images and determined
need. From July 2004, a guideline policy was implemented,
enabling the imaging sonographer to determine the need for
microbubble use on the basis of observed resting image qual-
ity. Under this standing order, a microbubble contrast agent
was used if reasonable attempts had been made to optimize
the echocardiographic images and the endocardium of 2 or
more left ventricular segments was not visualized adequately
to evaluate cardiac structure in systole and diastole. This
decision, in turn, triggered implementation of a protocol for
immediate intravenous access and preparation of a contrast
agent, initiated by a page to a central number to notify
the assigned individual from a team of echocardiography
nurses. The nurse then prepared the contrast agent, obtained
intravenous access, and, when requested by the sonographer,
administered the contrast agent. (All registered nurses and
sonographers working in the stress echocardiography area
had been trained in contrast agent administration and in
optimization of image acquisition according to online, real-
time image appearance.) From July 2004 to November 2005,
the contrast agents perﬂutren protein-type A microspheres
(Optison; Amersham Health, Inc, Princeton, New Jersey)
and perﬂutren lipid microspheres (Deﬁnity; Bristol-Myers
Squibb Medical Imaging Inc, North Billerica, Massachusetts)
were used on alternate months, to enable the standing order.
Beforethistime,contrastagentselectionwasatthediscretion
of the ordering physician.
2.2. Measurements. All clinical data were prospectively
entered into a database at the time of the stress echocar-
diogram. Demographic variables such as sex and age were
collected. Information on a self-reported history of coronary
artery disease (CAD) (e.g., prior myocardial infarction,
percutaneous, or surgical revascularization) was obtained.
Weight and height were measured and body mass index
(BMI) was calculated. BMI was unavailable for 202 patients
(1%). A resting electrocardiogram was considered abnormal
if it contained pathologic Q waves, resting ST-T wave
abnormalities, left bundle branch block, or left ventricular
hypertrophy. The stress-testing methods included echocar-
diography with dobutamine or treadmill exercise. Major risk
factors for CAD were also identiﬁed, including hypertension,
diabetes, a family history of CAD, and hyperlipidemia.
Smoking status was evaluated but considered separately.
Since smoking is associated with chronic obstructive pul-
monary disease and, hence, with poor quality images,
we postulated that this variable could be used to predictCardiology Research and Practice 3
Table 1: Clinical characteristics of the studied population of
patients.
Characteristic Value
∗
(N = 15,253)
Age, y 64.4 ±13.4
Male sex 8,251 (54)
Body mass index 28.5 ±6.1
Dobutamine stress echocardiography 6,522 (43)
Resting ejection fraction, % 59 ±8
Smoking (current or past) 7,862 (52)
Major risk factors (>2, smoking excluded) 4,282 (28)
Diabetes 2,811 (18)
Family history of CAD 5,853 (38)
Hypertension 9,022 (59)
Dyslipidemia 9,655 (63)
Known CAD (e.g., angina, MI, revascularization) 3,372 (22)
Prior CABG 1,455 (10)
Prior PCI 1,754 (11)
Prior MI 1,809 (12)
Abnormal ECG 7,663 (50)
Left bundle branch block 406 (3)
Pathologic Q waves 1,333 (9)
Resting ST-T wave abnormalities 7,257 (48)
Left ventricular hypertrophy 581 (4)
β-Blocker use 6,030 (40)
Calcium channel blocker use 2,665 (17)
Contrast agent use 3,713 (24)
CABG, coronary artery bypass graft; CAD, coronary artery disease; ECG,
electrocardiogram; MI, myocardial infarction; PCI, percutaneous coronary
intervention.
∗Categorical data are expressed as number of patients and percentage of
sample; continuous data are expressed as mean ± SD.
microbubble contrast agent use. Use of β-blockers and
calcium channel blockers was also recorded. Table 1 shows
clinical characteristics of the cohort.
2.3. Statistical Analysis. Continuous variables are presented
as mean ± SD; discrete variables are presented as frequency
distribution.Meanswerecomparedusing2-sampleindepen-
dent t test, and categorical variables were compared using
conventional χ2 testing. A multivariate logistic regression
model was built to evaluate the statistical signiﬁcance of the
association between identiﬁed pretest variables and use of a
microbubble contrast agent during stress echocardiography.
Variables were tested individually in a univariate model, and
those that achieved a level of signiﬁcance (P<. 20) were
tested in a multivariate stepwise logistic regression.
BMI was represented by 4 categorical variables; hence,
no values for univariate analysis were reported. However,
univariate analysis is included for BMI measured on a
continuous scale. Variables with signiﬁcance (P<. 05) in
multivariate analysis were kept in the ﬁnal score model. SAS
PROC LOGISTIC (SAS Institute Inc, Cary, North Carolina)
was used to obtain maximum likelihood estimates of the
parameter coeﬃcients. Multiplicative interaction between
sex and BMI and smoking and BMI, as well as between type
of stress and BMI, was tested and did not show statistical
signiﬁcance. Accordingly, no interaction terms were retained
in the ﬁnal model. The model’s goodness of ﬁt was assessed
using the Hosmer-Lemeshow test. A low χ2 statistic with a
high P value indicates that the logistic function ﬁts the data
adequately.
Forourscore,weclassiﬁedBMI(kg/m2)into5categories
with associated point allocation: BMI <25, 0 point; BMI 25
to 30, 1 point; BMI >30 to 35, 2 points; BMI >35 to 40, 3
points;andBMI>40,4points.Electrocardiogramanomalies,
smoking, referral for dobutamine stress echocardiography,
major cardiovascular risk factors (more than 2 and other
than smoking), a previous history of CAD, and age 65 years
and older were transformed to binary variables (i.e., 1 if
present and 0 if not). An arbitrary cutoﬀ point of 65 years
waschosenforage.Thiscutoﬀwasclosetothecohort’smean
age, and changing the cutoﬀ point by adding or subtracting
10 years did not change the odds ratio appreciably.
The derived score was simply the arithmetic sum of the
predictive variables of the model, and an increasing weight
was accorded to an increasing BMI. Scores ranged from 0 to
11. The increasing cumulative incidence proportion of con-
trast agent use according to the score was tested with χ2 for
trend (Cochran-Armitage). A univariate logistic regression
ofthetotalscoreasapredictorofmicrobubblecontrastagent
use was also performed. Internal validation was conducted
by bootstrap repeated-sampling method (1000 samples with
replacement),andpredictorsofcoeﬃcientsfromthesamples
were recorded. Mean and standard error of these coeﬃcients
were compared with those obtained from the full cohort to
conﬁrm the robustness of the model.
3. Results
T h ep r i m a r yo u t c o m e ,d e ﬁ n e da st h eu s eo fam i c r o b u b b l e
contrast agent during stress echocardiography, occurred in
3713 (24%) of the 15253 patients in the study group.
A microbubble contrast agent was used in 2251 patients
(35%) of the group undergoing dobutamine stress echocar-
diography and in 1467 (17%) of the group undergoing
exercise stress echocardiography (P<. 001) (Figure 2).
The cumulative incidence proportion of contrast agent use
signiﬁcantly diﬀered according to the period for which it
was calculated. From November 2003 to July 2004, when
the decision to use a contrast agent depended on physician
review of resting images and direct order to give a contrast
agent, the cumulative incidence proportion was 15.6%,
compared with 28.5% from July 2004 to November 2005,
when the decision to give a contrast agent was sonographer-
driven, based on standing protocol (P<. 001). Image quality
was judged to be improved by the use of contrast in 3445
cases (93%), unchanged in 215 cases (6%), and worsened
in 53 cases (1%). Thirteen predictors were tested in the
multivariate analysis and 11 variables were retained in the
ﬁnal score model, including 4 categorical variables for BMI
(Table 2). The Hosmer-Lemeshow statistic was 10.89 (P =
.21), reﬂecting an appropriate ﬁt of the model. The allocated4 Cardiology Research and Practice
Stress echocardiography
(November 2003-November 2005)
(N = 15253)
Dobutamine
(n = 6522 [43%])
Exercise
(n = 8731 [57%])
Contrast
agent
(n = 2251 [35%])
No contrast
agent
(n = 4271 [65%])
Contrast
agent
(n = 1462 [17%])
No contrast
agent
(n = 7269 [83%])
Figure 2: Flowchart of patients included in analyses.
Table 2: Signiﬁcant predictors of contrast agent use included in the ﬁnal score model and the allocated score values.
Predictor Univariate analysis Multivariate analysis Allocated score
β Coeﬃcient P value OR (95% CI) β Coeﬃcient P value OR (95% CI)
Age ≥65 y 0.38 <.001 1.46 (1.35–1.57) 0.28 <.001 1.32 (1.21–1.44) 1
Male sex 0.21 <.001 1.23 (1.14–1.32) 0.21 <.001 1.23 (1.13–1.34) 1
Smoking 0.25 <.001 1.29 (1.2–1.39) 0.12 .003 1.13 (1.04–1.23) 1
Multiple (>2) risk factors for CAD
∗ 0.5 <.001 1.65 (1.53–1.79) 0.13 .005 1.13 (1.04–1.24) 1
BMI
†‡
<25 0
25–30 — — — 0.57 <.001 1.76 (1.57–1.98) 1
>30–35 — — — 1.33 <.001 3.79 (3.35–.26) 2
>35–40 — — — 1.78 <.001 5.94 (5.11–6.90) 3
>40 — — — 2.12 <.001 8.36 (6.92–10.09) 4
Dobutamine stress echocardiography
§ 0.96 <.001 2.62 (2.43–2.83) 0.76 <.001 2.13 (1.96–2.32) 1
Previous history of CAD
// 0.49 <.001 1.63 (1.50–1.78) 0.31 <.001 1.36 (1.23–1.50) 1
Abnormal ECG
¶ 0.28 <.001 1.32 (1.23–1.43) 0.11 .01 1.11 (1.03–1.21) 1
BMI, body mass index; CAD, coronary artery disease; CI, conﬁdence interval; ECG, electrocardiogram; OR, odds ratio.
∗Risk factors include hypertension, diabetes, hyperlipidemia, and family history of CAD.
†Ellipses indicate not applicable.
‡Reference category is a BMI lower than 25.
§Results of dobutamine stress echocardiography compared with results of treadmill stress echocardiography.
//Includes prior myocardial infarction and prior percutaneous coronary intervention or coronary artery bypass graft.
¶Includes those showing left ventricular hypertrophy, pathologic Q waves, left bundle branch block, or resting ST-T wave abnormalities.
score for every variable ﬁnally retained is shown in Table 2.
Because of increased strength of association with higher
BMI and outcome, an increasing score weight was allocated
to increasingly higher BMI levels. Regression coeﬃcients
and odds ratios for BMI as continuous variables as well as
other variables that were not retained in the ﬁnal model are
presented in Table 3.
All signiﬁcant variables showed a positive association
with microbubble contrast agent use. BMI (particularly BMI
>40) and dobutamine stress echocardiography were the 2
variables most likely to predict outcome. A clear gradient
of association existed between increasing BMI and outcome.
In addition, the computed score in univariate analysis was
f o u n dt ob eag o o dp r e d i c t o ro fo u t c o m e .Figure 3 shows the
distribution of the scores, which followed a normal distribu-
tion pattern; Figure 4 shows the relation between computed
score and cumulative incidence proportion of contrast agent
use (Cochran-Armitage test for trend, P<. 001). Because the
number of patients who had an individual score of 8, 9, 10,
or 11 was small, these patients were combined into 1 group
labeled “8+.” The cumulative incidence proportion for use of
contrast agent was 8% for a score of 1, 21% for 4, and 58%
for 8+ (P for trend, <.001). Receiver operator characteristic
curves analysis was performed (Figure 5). A cutoﬀ score of
5 had the best discriminative properties—66% sensitivity
and 64% speciﬁcity—to correctly identify individuals who
required intravenous contrast agents. Area under the curve
was 0.70.
4. Discussion
Our results suggest that clinical information, which is
routinely available at presentation for the stress echocar-
diography procedure, can be used to identify patients in
whom the use of intravenous microbubble contrast agentsCardiology Research and Practice 5
Table 3: Tested variables not included in the ﬁnal score model.
Univariate analysis Multivariate analysis
β Coeﬃcient P value OR (95% CI) β Coeﬃcient P value OR (95% CI)
Calcium channel blocker use 0.18 .003 1.19 (1.08–1.32) −0.06 .33 0.95 (0.85–1.05)
β-Blocker use 0.41 <.001 1.5 (1.39–1.62) 0.07 .11 1.07 (0.98–1.17)
BMI (per 10-unit increase) 1.06 <.001 2.88 (2.67–3.08) 1.04 <.001 2.83 (2.64–3.04)
Total score∗ (per 2-unit increase) 0.84 <.001 2.31 (2.20–2.42) — — —
BMI, body mass index; CI, conﬁdence interval; OR, odds ratio.
∗Ellipses indicate not applicable.
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Figure 3: Distribution of pretest scores in the cohort of 15,253
patients. “8+” indicates an individual score of 8, 9, 10, or 11.
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Figure 4: Cumulative incidence proportion (CIP) of contrast
agent use according to pretest score. Below the x-axis label, the
denominators indicate the number of patients with each score and
the numerators indicate the corresponding subset of patients who
had contrast agent use. “8+” indicates an individual score of 8, 9,
10, or 11.
is likely to be needed. This information, including age, sex,
smoking, presence of risk factors for CAD, history of CAD,
electrocardiogram anomalies, and referral for dobutamine
stress echocardiography can easily be determined before
imaging. Admittedly, our observation of frequent use in
obese patients was not that surprising. Obese patients are
often diﬃcult to image, and the ﬁnding of a positive
association between a high BMI and the use of microbub-
ble contrast agents is consistent with intuitive knowledge.
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Figure 5: Receiver operating characteristic curve for total pretest
score. Area under the curve is 0.70.
Similarly, the more frequent use of microbubble contrast
agents during dobutamine stress echocardiography might
be explained by the preordained availability of requisite
intravenous access and trained personnel. However, during
treadmill echocardiographic stress testing, poststress image
acquisition is frequently more challenging than during
dobutamine echocardiographic stress testing because of lim-
ited image acquisition time and frequent hyperventilation.
Unfortunately, the quality of the baseline resting images
cannot always predict the quality of the postexercise images.
Therefore, awareness of need for microbubble contrast agent
use at presentation for exercise stress testing would be very
useful.
The positive association found between an abnormal
baseline electrocardiogram, the presence of multiple risk
factors, and microbubble contrast agent use is interesting.
These variables are not likely to be causally associated with
poor endocardial border deﬁnition per se, but a plausible
explanation is that their presence is associated with a higher
prevalence of CAD and, hence, wall motion abnormalities.
To increase the level of conﬁdence in interpretation of wall
motion in the presence of either an abnormal baseline
electrocardiogramormultipleriskfactors,echocardiography
consultantsmaybemorelikelytouseamicrobubblecontrast
agent.
The approach used to devise our prediction score system
is similar to that of Croft et al. [9], who developed a tool6 Cardiology Research and Practice
to clinically predict nerve function impairment in leprosy
patients, and is also derived from Antman et al. [10], who
published the Thrombosis in Myocardial Infarction risk
score for unstable angina and non-ST-elevation myocardial
infarction.
Our contrast use prediction score was designed to be
easily computable before imaging and simple to remember.
In low- or medium-volume centers where contrast imple-
mentation is yet evolving, this screening method could allow
more eﬃcient resource distribution and could be used to
guide procedural ﬂow at diﬀerent levels of intensity. For
example, the availability of appropriately trained personnel
to perform contrast imaging studies could be facilitated by
designating an area where patients preidentiﬁed with screen-
ing could be preferentially directed, and if 2-dimensional
imaging was conﬁrmed to be inadequate, contrast agents
could be used without further delay. Ideally, the score would
beusedtoidentifycandidatepatients,andintravenousaccess
would be placed even before imaging was initiated. This
strategy could potentially be most useful in patients who are
scheduled to have exercise stress testing, because the quality
of resting images may not predict that of the postexercise
images.
Our results are derived from a high volume stress
echocardiography laboratory with sonographers accustomed
to take the decision to directly proceed to contrast usage
or not. Clinical practice patterns, sonographers familiarity
with contrast usage, and even patient population may vary
signiﬁcantly from center to center and could possibly limit
the applicability of our method in certain circumstances.
Furthermore, given the discriminatory potential of our
score, a proportion of patients would have a misclassiﬁed
prediction of microbubble contrast agent use. To overcome
this limitation, a higher cutoﬀ point could be used to make
a decision. A cutoﬀ score of 7 or more would lead to
a speciﬁcity of 91% at the price of a sensitivity of 27%.
With the objective of the score being to quickly identify
individualsmostlikelytorequiremicrobubblecontrastagent
use, speciﬁcity could be favored because contrast agents can
be given later and as needed on the basis of the results of
the initial imaging. This strategy would be most relevant
in patients presenting for dobutamine stress testing, in
whom intravenous access is already present and only the
decision to administer a contrast agent needs to be made.
The implications of inappropriately directing a patient to a
room where all equipment settings are ready for contrast
imaging are negligible. If, on the basis of resting images, it
is determined that the patient does not need a microbubble
contrast agent, clinical procedures will not be delayed, no
increase in cost will be incurred, and the patient will not
be exposed to any additional risk. Implementation of the
contrast use prediction score should allow gains in eﬃciency
and facilitate the appropriate use of contrast agents when
indicated.
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